MUMBAI, India, June 16 -- Intellectual Property India has published a patent application (202611053578 A) filed by Dr. Arvind Kumar; Dr. Arunadevi. P; Dr. Hari Krishna Karri; Dr. Nookesh Kotipalli; Dr. Prasanna Shama Khandige; Dr Akash Ved; Dr Ankita Wal; Mrs Vidya Harshad Kapurkar; Yogita Laxmikant Rajgandhi; and Dr. Ganesh Prasad Patel, Moradabad, Uttar Pradesh, on April 27, for 'novel biomarkers for alzheimer's disease and related dementias using plasma proteomics for early diagnosis, prognosis, and therapeutic monitoring.'
Inventor(s) include Dr. Arvind Kumar; Dr. Arunadevi. P; Dr. Hari Krishna Karri; Dr. Nookesh Kotipalli; Dr. Prasanna Shama Khandige; Dr Akash Ved; Dr Ankita Wal; Mrs Vidya Harshad Kapurkar; Yogita Laxmikant Rajgandhi; and Dr. Ganesh Prasad Patel.
The application for the patent was published on June 5, under issue no. 23/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to novel plasma proteomic biomarkers for early diagnosis, prognosis, and therapeutic monitoring of Alzheimer's disease and related dementias. The invention identifies a panel of plasma proteins significantly associated with neurodegenerative pathology through high-throughput proteomic screening of patient plasma samples. The identified biomarkers include neurofilament light chain, phosphorylated tau species, complement proteins, apolipoprotein fragments, inflammatory mediators, oxidative stress proteins, synaptic degeneration markers, and proprietary peptide signatures. The invention utilizes mass spectrometry, aptamer-based proteomics, ELISA validation, and machine learning algorithms to generate highly accurate diagnostic models. The biomarker panel demonstrates superior sensitivity and specificity compared with conventional diagnostic approaches and enables differentiation among Alzheimer's disease, vascular dementia, Lewy body dementia, and frontotemporal dementia. Additionally, the invention predicts progression from mild cognitive impairment to Alzheimer's disease and monitors treatment response. The technology offers a non-invasive, scalable, and cost-effective alternative to PET imaging and cerebrospinal fluid testing."
Disclaimer: Curated by HT Syndication.
